Protalix Biotherapeutics Inc (PBDA)

Currency in EUR
1.300
-0.040(-2.99%)
Closed·
PBDA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PBDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3001.340
52 wk Range
0.6402.700
Key Statistics
Bid/Ask
1.30 / 1.34
Prev. Close
1.3
Open
1.33
Day's Range
1.3-1.34
52 wk Range
0.64-2.7
Volume
-
Average Volume (3m)
1.48K
1-Year Change
42.7%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PBDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Protalix Biotherapeutics Inc Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.

Employees
213
Market
Germany

Compare PBDA to Peers and Sector

Metrics to compare
PBDA
Peers
Sector
Relationship
P/E Ratio
32.6x−5.2x−0.5x
PEG Ratio
−1.39−0.190.00
Price/Book
2.8x3.1x2.6x
Price / LTM Sales
2.1x11.2x3.2x
Upside (Analyst Target)
-110.3%40.5%
Fair Value Upside
Unlock12.6%4.4%Unlock

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.05 / --
Revenue / Forecast
10.11M / --
EPS Revisions
Last 90 days

PBDA Income Statement

People Also Watch

101.17
CRDO
+2.80%
14.45
PONY
-4.43%
51.030
SMR
+6.65%
120.00
CRWV
-4.80%
16.9500
QUBT
-2.98%

FAQ

What Stock Exchange Does Protalix Biotherapeutics Inc Trade On?

Protalix Biotherapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Protalix Biotherapeutics Inc?

The stock symbol for Protalix Biotherapeutics Inc is "PBDA."

What Is the Protalix Biotherapeutics Inc Market Cap?

As of today, Protalix Biotherapeutics Inc market cap is 105.10M.

What Is Protalix Biotherapeutics Inc's Earnings Per Share (TTM)?

The Protalix Biotherapeutics Inc EPS (TTM) is 0.05.

From a Technical Analysis Perspective, Is PBDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Protalix Biotherapeutics Inc Stock Split?

Protalix Biotherapeutics Inc has split 1 times.

How Many Employees Does Protalix Biotherapeutics Inc Have?

Protalix Biotherapeutics Inc has 213 employees.

What is the current trading status of Protalix Biotherapeutics Inc (PBDA)?

As of 25 Jul 2025, Protalix Biotherapeutics Inc (PBDA) is trading at a price of 1.30, with a previous close of 1.30. The stock has fluctuated within a day range of 1.30 to 1.34, while its 52-week range spans from 0.64 to 2.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.